In a breakthrough that challenges long-held conventions in organic synthesis, researchers have successfully created a class ...

BARCELONA, September 14, 2024--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ...

A groundbreaking discovery by researchers at the University of California, Los Angeles (UCLA) has challenged a long-standing ...

Bicycle Therapeutics has developed a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle) product platform, and will gain funding for phase 1 and phase 1b clinical trial ...

The company is developing a new class of drugs based on its proprietary ‘Bicycle’ bicyclic peptide product platform, which aims to combine the best qualities of several therapeutic entities in ...

EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...